These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27730438)

  • 1. Clinical Trials and a View Toward the Future of ADPKD.
    Kim H; Hwang YH
    Adv Exp Med Biol; 2016; 933():105-121. PubMed ID: 27730438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic approaches to autosomal dominant polycystic kidney disease.
    LaRiviere WB; Irazabal MV; Torres VE
    Transl Res; 2015 Apr; 165(4):488-98. PubMed ID: 25438190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Pharmacokinetics and Implications for Practice.
    Hines CB; Hooper GL; Collins-Yoder A
    Nephrol Nurs J; 2020; 47(2):145-150. PubMed ID: 32343088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on tolvaptan for autosomal dominant polycystic kidney disease.
    Poch E; Rodas L; Blasco M; Molina A; Quintana L
    Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?
    Pisani A; Riccio E; Bruzzese D; Sabbatini M
    BMC Nephrol; 2018 Oct; 19(1):282. PubMed ID: 30348113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathophysiology, epidemiology, clinical presentation, diagnosis and treatment options for autosomal dominant polycystic kidney disease].
    Noël N; Rieu P
    Nephrol Ther; 2015 Jul; 11(4):213-25. PubMed ID: 26113401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].
    Cornec-Le Gall E; Le Meur Y
    Nephrol Ther; 2014 Nov; 10(6):433-40. PubMed ID: 25086476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic interventions for autosomal dominant polycystic kidney disease.
    Edelstein CL
    Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV; Torres VE; Hogan MC; Glockner J; King BF; Ofstie TG; Krasa HB; Ouyang J; Czerwiec FS
    Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials.
    Myint TM; Rangan GK; Webster AC
    Nephrology (Carlton); 2014 Apr; 19(4):217-26. PubMed ID: 24460701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better understanding of ADPKD results in potential new treatment options: ready for the cure?
    Meijer E; de Jong PE; Peters DJ; Gansevoort RT
    J Nephrol; 2008; 21(2):133-8. PubMed ID: 18446706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open?
    Kou P; Wei S; Xiong F
    Curr Med Chem; 2019; 26(16):2962-2973. PubMed ID: 29600752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy.
    Wüthrich RP; Serra AL; Kistler AD
    Kidney Blood Press Res; 2009; 32(5):380-7. PubMed ID: 19887826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological management of polycystic kidney disease.
    Wüthrich RP; Mei C
    Expert Opin Pharmacother; 2014 Jun; 15(8):1085-95. PubMed ID: 24673552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in management of autosomal-dominant polycystic kidney disease.
    Potts JW; Mousa SA
    Am J Health Syst Pharm; 2017 Dec; 74(23):1959-1968. PubMed ID: 29167138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitors of intra-cystic secretion: novel therapies in ADPKD (Autosomal Dominant Polycystic Kidney Disease)].
    Miranda N; Miranda F; Rinaldi L; Stratigis S; Capasso G
    G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ADPKD treatment: Tolvaptan and Octreotide].
    Galliani M; Chicca S; Vitaliano E; Moscaritolo E; Calvaruso L; Iorio F; Paone A
    G Ital Nefrol; 2019 Dec; 36(6):. PubMed ID: 31830392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.